Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis

doi:10.3947/ic.2011.43.1.1

Journal List > Infect Chemother > v.43(1) > 1035069

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, and The Korean Society of Clinical Microbiology: Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis

Special Article

Infection & Chemotherapy

Infection & Chemotherapy 2011; 43(1): 1-25.

Published online: 28 February 2011

DOI: https://doi.org/10.3947/ic.2011.43.1.1

Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis

The Korean Society of Infectious DiseasesThe Korean Society for ChemotherapyKorean Association of Urogenital Tract Infection and InflammationThe Korean Society of Clinical Microbiology

Correspondence to The Committee of the Korean Society for Chemotherapy for Diagnosis and Treatment Guidelines of Gastrointestinal Infection. Korean Society for Chemotherapy, Asterium #1203, Majellan 21, Samseong-dong 158-10, Kangnam-gu, Seoul 135-880, Korea. Tel: +82-2-557-1755, Fax: +82-2-6499-1755, ksc@ksac.or.kr

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The US guideline for urinary tract infections has been applied in our country. However, clinical characteristics, etiology and antimicrobial susceptibility could differ from country to country, therefore, we tried to make diagnosis and treatment guideline for urinary tract infections based on published articles of antimicrobial treatment efficacy of UTI and available antimicrobial susceptibility of major pathogens causing urinary tract infections in our country, which reflects clinical situation in Korea. This guideline was developed by the committee of the Korean Society for Chemotherapy, and covers asymptomatic bacteriuria, bacterial prostatitis, uncomplicated and complicated urinary tract infections.

Keywords: Asymptomatic bacteriuria, Cystitis, Pyelonephritis, Complicated urinary tract infection, Bacterial prostatitis, Guideline

Figures and Tables

Table 1

Recommendation of Strength and Quality of Evidence

References

1. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America. American Society of Nephrology. American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005. 40:643–654.

2. Shin JC, Yoo JH, Park JW, Park S, Ahn SJ, Park CI. Difference of organism and their antibiotics sensitivity from urine culture in symptomatic urinary tract infection of spinal cord injury patients. J Korean Acad Rehabil Med. 2008. 32:38–44.

3. Smaill F, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007. (2):CD000490.

4. Villar J, Lydon-Rochelle MT, Gülmezoglu AM, Roganti A. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev. 2000. (2):CD000491.

5. Bayrak O, Cimentepe E, Inegöl I, Atmaca AF, Duvan CI, Koç A, Turhan NO. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy? Int Urogynecol J Pelvic Floor Dysfunct. 2007. 18:525–529.

6. Tal S, Guller V, Levi S, Bardenstein R, Berger D, Gurevich I, Gurevich A. Profile and prognosis of febrile elderly patients with bacteremic urinary tract infection. J Infect. 2005. 50:296–305.

7. Nicolle LE. Urinary tract infections in the elderly. Clin Geriatr Med. 2009. 25:423–436.

8. Hedin K, Petersson C, Widebäck K, Kahlmeter G, Mölstad S. Asymptomatic bacteriuria in a population of elderly in municipal institutional care. Scand J Prim Health Care. 2002. 20:166–168.

9. Nicolle LE. Asymptomatic bacteriuria in the elderly. Infect Dis Clin North Am. 1997. 11:647–662.

10. Rodhe N, Löfgren S, Matussek A, André M, Englund L, Kühn I, Mölstad S. Asymptomatic bacteriuria in the elderly: high prevalence and high turnover of strains. Scand J Infect Dis. 2008. 40:804–810.

11. Wing DA, Rumney PJ, Preslicka CW, Chung JH. Daily cranberry juice for the prevention of asymptomatic bacteriuria in pregnancy: a randomized, controlled pilot study. J Urol. 2008. 180:1367–1372.

12. Lumbiganon P, Villar J, Laopaiboon M, Widmer M, Thinkhamrop J, Carroli G, Duc Vy N, Mignini L, Festin M, Prasertcharoensuk W, Limpongsanurak S, Liabsuetrakul T, Sirivatanapa P. World Health Organization Asymptomatic Bacteriuria Trial Group. One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial. Obstet Gynecol. 2009. 113:339–345.

13. Harding GK, Zhanel GG, Nicolle LE, Cheang M. Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002. 347:1576–1583.

14. Dalal S, Nicolle L, Marrs CF, Zhang L, Harding G, Foxman B. Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis. 2009. 49:491–497.

15. Boscia JA, Kobasa WD, Knight RA, Abrutyn E, Levison ME, Kaye D. Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. JAMA. 1987. 257:1067–1071.

16. Abrutyn E, Mossey J, Berlin JA, Boscia J, Levison M, Pitsakis P, Kaye D. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med. 1994. 120:827–833.

17. Nicolle LE, Bjornson J, Harding GK, MacDonell JA. Bacteriuria in elderly institutionalized men. N Engl J Med. 1983. 309:1420–1425.

18. Nicolle LE, Mayhew WJ, Bryan L. Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women. Am J Med. 1987. 83:27–33.

19. Ouslander JG, Schapira M, Schnelle JF, Uman G, Fingold S, Tuico E, Nigam JG. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med. 1995. 122:749–754.

20. Mohler JL, Cowen DL, Flanigan RC. Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. J Urol. 1987. 138:336–340.

21. Maynard FM, Diokno AC. Urinary infection and complications during clean intermittent catheterization following spinal cord injury. J Urol. 1984. 132:943–946.

22. Harding GK, Nicolle LE, Ronald AR, Preiksaitis JK, Forward KR, Low DE, Cheang M. How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. Ann Intern Med. 1991. 114:713–719.

23. Warren JW, Anthony WC, Hoopes JM, Muncie HL Jr. Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients. JAMA. 1982. 248:454–458.

24. Leone M, Perrin AS, Granier I, Visintini P, Blasco V, Antonini F, Albanèse J, Martin C. A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients. Intensive Care Med. 2007. 33:726–729.

25. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE. Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010. 50:625–663.

26. Grabe M, Forsgren A, Björk T, Hellsten S. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol. 1987. 6:11–17.

27. Olsen JH, Friis-Møller A, Jensen SK, Korner B, Hvidt V. Cefotaxime for prevention of infectious complications in bacteriuric men undergoing transurethral prostatic resection. A controlled comparison with methenamine. Scand J Urol Nephrol. 1983. 17:299–301.

28. Grabe M, Forsgren A, Hellsten S. The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol. 1984. 18:37–42.

29. Allan WR, Kumar A. Prophylactic mezlocillin for transurethral prostatectomy. Br J Urol. 1985. 57:46–49.

30. Rao PN, Dube DA, Weightman NC, Oppenheim BA, Morris J. Prediction of septicemia following endourological manipulation for stones in the upper urinary tract. J Urol. 1991. 146:955–960.

31. Cafferkey MT, Falkiner FR, Gillespie WA, Murphy DM. Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother. 1982. 9:471–477.

32. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med. 2002. 113:Suppl 1A. 35S–44S.

33. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006. 50:2251–2254.

34. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA, Hoban DJ. NAUTICA Group. Antibiotic resistance in Escherichia coli out patient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006. 27:468–475.

35. Wie SH, Chang UI, Kim HW, Kim YS, Kim SY, Hur J, Kim SI, Kim YR, Kang MW. Clinical features and antimicrobial resistance among clinical isolates of women with community-acquired acute pyelonephritis in 2001-2006. Infect Chemother. 2007. 39:9–16.

36. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol. 2003. 13:144–150.

37. Vila J, Simon K, Ruiz J, Horcajada JP, Velasco M, Barranco M, Moreno A, Mensa J. Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis. 2002. 186:1039–1042.

38. Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med. 1999. 159:53–58.

39. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005. 71:933–942.

40. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001. 33:615–621.

41. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005. 71:933–942.

42. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Infectious Diseases Society of America (IDSA). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999. 29:745–758.

43. Foxman B, Ki M, Brown P. Antibiotic resistance and pyelonephritis. Clin Infect Dis. 2007. 45:281–283.

44. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics. 2005. 23:1123–1142.

45. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents. 2008. 31:Suppl 1. S15–S18.

46. Hwang BY, Lee JG, Park DW, Lee YJ, Kim SB, Eom JS, Sohn JW, Cheong HJ, Kim WJ, Kim MJ, Park SC. Antimicrobial susceptibility of causative microorganisms in adults with acute pyelonephritis at one university-affiliated hospital in southwestern Seoul. Infect Chemother. 2003. 35:277–282.

47. Wie SH, Choi SM, Lee DG, Kim SY, Kim SI, Yoo JH, Shin WS, Kang MW. Antibiotic sensitivity of the causative organisms and use of antibiotics in women with community-acquired acute pyelonephritis. Korean J Infect Dis. 2002. 34:353–359.

48. McNulty CA, Richards J, Livermore DM, Little P, Charlett A, Freeman E, Harvey I, Thomas M. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother. 2006. 58:1000–1008.

49. Kahlmeter G, Menday P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO.SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother. 2003. 52:128–131.

50. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis. 2001. 33:89–94.

51. De Backer D, Christiaens T, Heytens S, De Sutter A, Stobberingh EE, Verschraegen G. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 10 year interval. J Antimicrob Chemother. 2008. 62:364–368.

52. Stamm WE. Measurement of pyuria and its relation to bacteriuria. Am J Med. 1983. 75:53–58.

53. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997. 44:49–60.

54. Tal S, Guller V, Levi S, Bardenstein R, Berger D, Gurevich I, Gurevich A. Profile and prognosis of febrile elderly patients with bacteremic urinary tract infection. J Infect. 2005. 50:296–305.

55. Nicolle LE. Urinary tract infections in the elderly. Clin Geriatr Med. 2009. 25:423–436.

56. Gleckman R, Blagg N, Hibert D, Hall A, Crowley M, Pritchard A, Warren W. Acute pyelonephritis in the elderly. South Med J. 1982. 75:551–554.

57. Kunin CM. Urinary tract infections in females. Clin Infect Dis. 1994. 18:1–10. quiz 11-2.

58. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA. 2005. 293:949–955.

59. Raz R, Rottensterich E, Leshem Y, Tabenkin H. Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother. 1994. 38:1176–1177.

60. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000. 283:1583–1590.

61. van Merode T, Nys S, Raets I, Stobberingh E. Acute uncomplicated lower urinary tract infections in general practice: clinical and microbiological cure rates after three- versus five-day treatment with trimethoprim. Eur J Gen Pract. 2005. 11:55–58.

62. Stein GE, Philip E. Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women. J Fam Pract. 1992. 34:180–184.

63. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA. 1995. 273:41–45.

64. Gossius G, Vorland L. A randomised comparison of single-dose vs. three-day and ten-day therapy with trimethoprim-sulfamethoxazole for acute cystitis in women. Scand J Infect Dis. 1984. 16:373–379.

65. Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borrild N, Bru JP, Mckinnon C, O'Doherty B, Spiegel W, Van Balen FA, Menday P. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis. 2002. 34:487–492.

66. Richard GA, Mathew CP, Kirstein JM, Orchard D, Yang JY. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology. 2002. 59:334–339.

67. Vogel T, Verreault R, Gourdeau M, Morin M, Grenier-Gosselin L, Rochette L. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ. 2004. 170:469–473.

68. Bach D, van den Berg-Segers A, Hübner A, van Breukelen G, Cesana M, Plétan Y. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. J Urol. 1995. 154:19–24.

69. Naber KG, Allin DM, Clarysse L, Haworth DA, James IG, Raini C, Schneider H, Wall A, Weitz P, Hopkins G, Ankel-Fuchs D. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents. 2004. 23:596–605.

70. Henry DC Jr, Bettis RB, Riffer E, Haverstock DC, Kowalsky SF, Manning K, Hamed KA, Church DA. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther. 2002. 24:2088–2104.

71. Henry DC, Nenad RC, Iravani A, Tice AD, Mansfield DL, Magner DJ, Dorr MB, Talbot GH. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Clin Ther. 1999. 21:966–981.

72. Pummer K. Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study. Am J Med. 1993. 94:108S–113S.

73. Goldstein EJ, Kahn RM, Alpert ML, Ginsberg BP, Greenway FL, Citron DM. Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. Am J Med. 1987. 82:284–287.

74. Stein GE, Philip E. Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women. J Fam Pract. 1992. 34:180–184.

75. Baker PC, Nelson DS, Schunk JE. The addition of ceftriaxone to oral therapy does not improve outcome in febrile children with urinary tract infections. Arch Pediatr Adolesc Med. 2001. 155:135–139.

76. Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med. 1999. 159:53–58.

77. Sanchez M, Collvinent B, Miró O, Horcajada JP, Moreno A, Marco F, Mensa J, Millá J. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emerg Med J. 2002. 19:19–22.

78. Büchi W, Casey PA. Experience with parenteral and sequential parenteral-oral amoxicillin/clavulanate (augmentin) in hospitalized patients. Infection. 1988. 16:306–312.

79. Gok F, Duzova A, Baskin E, Ozen S, Besbas N, Bakkaloglu A. Comparative study of cefixime alone versus intramuscular ceftizoxime followed by cefixime in the treatment of urinary tract infections in children. J Chemother. 2001. 13:277–280.

80. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Hoekstra JB, Bouter KP, Bravenboer B, Collet JT, Jansz AR, Hoepelman AI. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Care. 2000. 23:744–749.

81. Wheat LJ. Infection and diabetes mellitus. Diabetes Care. 1980. 3:187–197.

82. Geerlings SE, Brouwer EC, Gaastra W, Verhoef J, Hoepelman AI. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999. 48:535–539.

83. Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis. 1995. 21:316–322.

84. Chen MT, Huang CN, Chou YH, Huang CH, Chiang CP, Liu GC. Percutaneous drainage in the treatment of emphysematous pyelonephritis: 10-year experience. J Urol. 1997. 157:1569–1573.

85. Shokeir AA, El-Azab M, Mohsen T, El-Diasty T. Emphysematous pyelonephritis: a 15-year experience with 20 cases. Urology. 1997. 49:343–346.

86. Kamaliah MD, Bhajan MA, Dzarr GA. Emphysematous pyelonephritis caused by candida infection. Southeast Asian J Trop Med Public Health. 2005. 36:725–727.

87. Calvet HM, Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am. 2001. 15:407–421.

88. Forland M, Thomas V, Shelokov A. Urinary tract infections in patients with diabetes mellitus. Studies on antibody coating of bacteria. JAMA. 1977. 238:1924–1926.

89. Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents. 2003. 22:Suppl 2. 35–43.

90. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000. 160:797–805.

91. Wan YL, Lee TY, Bullard MJ, Tsai CC. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology. 1996. 198:433–438.

92. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993. 329:1328–1334.

93. Meiland R, Geerlings SE, Stolk RP, Netten PM, Schneeberger PM, Hoepelman AI. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med. 2006. 166:2222–2227.

94. Park Soo B, Lee SJ, Kim Wha Y, Huh Sik J, Kim Il J, Chang SG. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol. 2006. 40:332–338.

95. Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N'Dow J. ABACUS Research Group. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systemic review. J Urol. 2008. 179:1844–1849.

96. Roy C, Pfleger DD, Tuchmann CM, Lang HH, Saussine CC, Jacqmin D. Emphysematous pyelitis: findings in five patients. Radiology. 2001. 218:647–650.

97. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med. 2000. 160:678–682.

98. Nicolle LE. Consequences of asymptomatic bacteriuria in the elderly. Int J Antimicrob Agents. 1994. 4:107–111.

99. Loeb M, Bentley DW, Bradley S, Crossley K, Garibaldi R, Gantz N, McGeer A, Muder RR, Mylotte J, Nicolle LE, Nurse B, Paton S, Simor AE, Smith P, Strausbaugh L. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. Infect Control Hosp Epidemiol. 2001. 22:120–124.

100. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992. J Am Paraplegia Soc. 1992. 15:194–204.

101. Tambyah PA, Maki DG. The relationship between pyuria and infection in patients with indwelling urinary catheters: a prospective study of 761 patients. Arch Intern Med. 2000. 160:673–677.

102. Steward DK, Wood GL, Cohen RL, Smith JW, Mackowiak PA. Failure of the urinalysis and quantitative urine culture in diagnosing symptomatic urinary tract infections in patients with long-term urinary catheters. Am J Infect Control. 1985. 13:154–160.

103. Stéphan F, Sax H, Wachsmuth M, Hoffmeyer P, Clergue F, Pittet D. Reduction of urinary tract infection and antibiotic use after surgery: a controlled, prospective, before-after intervention study. Clin Infect Dis. 2006. 42:1544–1551.

104. Huang WC, Wann SR, Lin SL, Kunin CM, Kung MH, Lin CH, Hsu CW, Liu CP, Lee SS, Liu YC, Lai KH, Lin TW. Catheter-associated urinary tract infections in intensive care units can be reduced by prompting physicians to remove unnecessary catheters. Infect Control Hosp Epidemiol. 2004. 25:974–978.

105. Apisarnthanarak A, Thongphubeth K, Sirinvaravong S, Kitkangvan D, Yuekyen C, Warachan B, Warren DK, Fraser VJ. Effectiveness of multifaceted hospitalwide quality improvement programs featuring an intervention to remove unnecessary urinary catheters at a tertiary care center in Thailand. Infect Control Hosp Epidemiol. 2007. 28:791–798.

106. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med. 2006. 29:527–573.

107. Erickson RP, Merritt JL, Opitz JL, Ilstrup DM. Bacteriuria during follow-up in patients with spinal cord injury: I. Rates of bacteriuria in various bladder-emptying methods. Arch Phys Med Rehabil. 1982. 63:409–412.

108. Niël-Weise BS, van den Broek PJ. Urinary catheter policies for short-term bladder drainage in adults. Cochrane Database Syst Rev. 2005. (3):CD004203.

109. Kass EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians. 1956. 69:56–64.

110. Niël-Weise BS, van den Broek PJ. Antibiotic policies for short-term catheter bladder drainage in adults. Cochrane Database Syst Rev. 2005. (2):CD005428.

111. Niël-Weise BS, van den Broek PJ. Urinary catheter policies for long-term bladder drainage. Cochrane Database Syst Rev. 2005. (1):CD004201.

112. Rutschmann OT, Zwahlen A. Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients. Eur J Clin Microbiol Infect Dis. 1995. 14:441–444.

113. Gribble MJ, Puterman ML. Prophylaxis of urinary tract infection in persons with recent spinal cord injury: a prospective, randomized, double-blind, placebo-controlled study of trimethoprim-sulfamethoxazole. Am J Med. 1993. 95:141–152.

114. van den Broek PJ, Daha TJ, Mouton RP. Bladder irrigation with povidone-iodine in prevention of urinary-tract infections associated with intermittent urethral catheterisation. Lancet. 1985. 1:563–565.

115. Ball AJ, Carr TW, Gillespie WA, Kelly M, Simpson RA, Smith PJ. Bladder irrigation with chlorhexidine for the prevention of urinary infection after transurethral operations: a prospective controlled study. J Urol. 1987. 138:491–494.

116. Leone M, Perrin AS, Granier I, Visintini P, Blasco V, Antonini F, Albanèse J, Martin C. A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients. Intensive Care Med. 2007. 33:726–729.

117. Warren JW, Anthony WC, Hoopes JM, Muncie HL Jr. Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients. JAMA. 1982. 248:454–458.

118. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America. American Society of Nephrology. American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005. 40:643–654.

119. Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging. 2001. 18:243–254.

120. Pearman JW, Peterson GJ, Nash JB. The antimicrobial activity of urine of paraplegic patients receiving methenamine mandelate. Invest Urol. 1978. 16:91–98.

121. Raz R, Schiller D, Nicolle LE. Chronic indwelling catheter replacement before antimicrobial therapy for symptomatic urinary tract infection. J Urol. 2000. 164:1254–1258.

122. Harding GK, Nicolle LE, Ronald AR, Preiksaitis JK, Forward KR, Low DE, Cheang M. How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. Ann Intern Med. 1991. 114:713–719.

123. Dow G, Rao P, Harding G, Brunka J, Kennedy J, Alfa M, Nicolle LE. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis. 2004. 39:658–664.

124. Wen JG, Frøkiaer J, Jørgensen TM, Djurhuus JC. Obstructive nephropathy: an update of the experimental research. Urol Res. 1999. 27:29–39.

125. Grabe M, Bjerklund-Johansen TE, Botto H, Çek M, Naber KG, Tenke P, Wagenlehner F. Guidelines on urological infections. European Association of Urology Web site. Accessed May 2009. Available at:.

126. Klahr S. Obstructive nephropathy. Intern Med. 2000. 39:355–361.

127. Pourmand G, Abedi AR, Karami AA, Khashayar P, Mehrsai AR. Urinary infection before and after prostatectomy. Saudi J Kidney Dis Transpl. 2010. 21:290–294.

128. Heidenreich A, Desgrandschamps F, Terrier F. Modern approach of diagnosis and management of acute flank pain: review of all imaging modalities. Eur Urol. 2002. 41:351–362.

129. Jeong MK, Yoon JB. Bacteriological study of urinary tract infections. Korean J Urol. 1982. 23:739–744.

130. Dembry LM, Andriole VT. Renal and perirenal abscesses. Infect Dis Clin North Am. 1997. 11:663–680.

131. Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1997. 11:735–750.

132. Nicolle L. AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005. 16:349–360.

133. Tseng TY, Stoller ML. Obstructive uropathy. Clin Geriatr Med. 2009. 25:437–443.

134. Chen MY, Zagoria RJ, Saunders HS, Dyer RB. Trends in the use of unenhanced helical CT for acute urinary colic. AJR Am J Roentgenol. 1999. 173:1447–1450.

135. Hamm M, Wawroschek F, Weckermann D, Knöpfle E, Häckel T, Häuser H, Krawczak G, Harzmann R. Unenhanced helical computed tomography in the evaluation of acute flank pain. Eur Urol. 2001. 39:460–465.

136. Miller OF, Rineer SK, Reichard SR, Buckley RG, Donovan MS, Graham IR, Goff WB, Kane CJ. Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Urology. 1998. 52:982–987.

137. Niall O, Russell J, MacGregor R, Duncan H, Mullins J. A comparison of noncontrast computerized tomography with excretory urography in the assessment of acute flank pain. J Urol. 1999. 161:534–537.

138. Ruppert-Kohlmayr AJ, Stacher R, Preidler KW, Zigeuner R, Primus G, Ricabonna M, Szolar DH. [Native spiral computerized tomography in patients with acute flank pain--sense or nonsense?]. Rofo. 1999. 170:168–173.

139. Bove P, Kaplan D, Dalrymple N, Rosenfield AT, Verga M, Anderson K, Smith RC. Reexamining the value of hematuria testing in patients with acute flank pain. J Urol. 1999. 162:685–687.

140. Wang LJ, Ng CJ, Chen JC, Chiu TF, Wong YC. Diagnosis of acute flank pain caused by ureteral stones: value of combined direct and indirect signs on IVU and unenhanced helical CT. Eur Radiol. 2004. 14:1634–1640.

141. Rosenstein D, McAninch JW. Urologic emergencies. Med Clin North Am. 2004. 88:495–518.

142. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006. 50:1306–1314. discussion 1314-5.

143. Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, Yokoyama O, Yoshida M. Japanese Society of Neurogenic Bladder. Clinical guideline for male lower urinary tract symptoms. Int J Urol. 2009. 16:775–790.

144. Park HJ, Shin KY, Lee TY. The role of endourologic management for tuberculous ureteral stricture. Korean J Urol. 2001. 42:910–914.

145. Cho SY, Lee H, Cho YH, Lee SJ. Clinical manifestation of emphysematous pyelonephritis and risk factors for mortality. Infect Chemother. 2009. 41:30–35.

146. Janetschek G, Girstmair J, Semenitz E. [Percutaneous nephrostomy as a technic for emergency drainage: review of cases.]. Wien Med Wochenschr. 1991. 141:556–559.

147. Ahn JC, Choi JH, Lee CK, Choi S, Kim JC, Rhew HY. Percutaneous nephrostomy: experience in 276 cases. Korean J Urol. 1994. 35:1248–1253.

148. Bishop MC. Urosurgical management of urinary tract infection. J Antimicrob Chemother. 1994. 33:Suppl A. 75–91.

149. Pontin AR, Barnes RD. Medscape. Current management of emphysematous pyelonephritis. Nat Rev Urol. 2009. 6:272–279.

150. Thorne MB, Geraci SA. Acute urinary retention in elderly men. Am J Med. 2009. 122:815–819.

151. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Infectious Diseases Society of America and the Food and Drug Administration. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis. 1992. 15:Suppl 1. S216–S227.

152. Beck EM, Riehle RA Jr. The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. J Urol. 1991. 145:6–9. discussion 9-10.

153. McNeill SA, Hargreave TB. Members of the Alfaur Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol. 2004. 171:2316–2320.

154. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int. 2005. 95:354–357.

155. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003. 349:2387–2398.

156. Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J. Proscar Long-Term Efficacy and Safety Study Group. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004. 171:1194–1198.

157. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003. 92:262–266.

158. Brosnahan J, Jull A, Tracy C. Types of urethral catheters for management of short-term voiding problems in hospitalised adults. Cochrane Database Syst Rev. 2004. (1):CD004013.

159. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003. 170:530–547.

160. Ramsey S, Robertson A, Ablett MJ, Meddings RN, Hollins GW, Little B. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol. 2010. 24:185–189.

161. Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008. 77:643–650.

162. Lee SH, Kim DK, Kim JC, Lee KS, Lee JG, Park CH, Hong SJ, Kim CS, Park JK, Chung BH. The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting. Yonsei Med J. 2010. 51:432–437.

163. Nyman MA, Schwenk NM, Silverstein MD. Management of urinary retention: rapid versus gradual decompression and risk of complications. Mayo Clin Proc. 1997. 72:951–956.

164. Uppot RN. Emergent nephrostomy tube placement for acute urinary obstruction. Tech Vasc Interv Radiol. 2009. 12:154–161.

165. Bierer S, Ozgün M, Bode ME, Wülfing C, Piechota HJ. [Obstructive uropathy in adults.]. Aktuelle Urol. 2005. 36:329–336.

166. Kim SC, Wang CS. A clinical observation on 131 cases of hydronephrosis. Korean J Urol. 1978. 19:89–97.

167. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection. 1991. 19:Suppl 3. S119–S125.

168. Schneider H, Ludwig M, Hossain HM, Diemer T, Weidner W. The 2001 Giessen Cohort Study on patients with prostatitis syndrome--an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia. 2003. 35:258–262.

169. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002. 113:Suppl 1A. 14S–19S.

170. Bichler KH, Eipper E, Naber K, Braun V, Zimmermann R, Lahme S. Urinary infection stones. Int J Antimicrob Agents. 2002. 19:488–498.

171. Romero Culleres G, Sugranes JC, Planells Romeo I, Gimenez Perez M. Characteristics of urinary tract infections in different patient subpopulations and depending on the bladder emptying system. Actas Urol Esp. 2010. 34:251–257.

172. Barros M, Martinelli R, Rocha H. Enterococcal urinary tract infections in a university hospital: clinical studies. Braz J Infect Dis. 2009. 13:294–296.

173. Johansen TE, Cek M, Naber KG, Stratchounski L, Svendsen MV, Tenke P. PEP and PEAP-study investigators. Board of the European Society of Infections in Urology. Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int J Antimicrob Agents. 2006. 28:Suppl 1. S91–S107.

174. Kumazawa J, Matsumoto T. Bergan T, editor. Complicated urinary tract infection. Urinary tract infections: molecular pathogenesis and clinical management. 1997. Basel: Karger;19–26.

175. Chevalier RL, Klahr S. Therapeutic approaches in obstructive uropathy. Semin Nephrol. 1998. 18:652–658.

176. Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs. 1997. 53:583–592.

177. McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Am J Med. 2005. 118:1331–1339.

178. Irani J, Brown CT, van der Meulen J, Emberton M. A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int. 2003. 92:937–942.

179. Oh CY, Lee SH, Yoo SJ, Chung BH. Korean urologist's view of practice patterns in diagnosis and management of benign prostatic hyperplasia: a nationwide survey. Yonsei Med J. 2010. 51:248–252.

180. DasGupta R, Sullivan R, French G, O'Brien T. Evidence-based prescription of antibiotics in urology: a 5-year review of microbiology. BJU Int. 2009. 104:760–764.

181. Hwang SD, Park KS, Jeon BS, Kim YJ, Lee SH, Lee KS, Yoon SY, Lee SC. Clinical risk factors for bacteremia in patients with acute pyelonephritis. Korean J Nephrol. 2009. 28:418–423.

182. Kim KY, Kim CS, Lim DH. The ciprofloxacin resistance pattern of Escherichia coli isolated from female patients with community-acquired urinary tract infection in the Jeonnam and Gwangju region for the recent 2-years. Korean J Urol. 2008. 49:540–548.

183. Segura JW. Staghorn calculi. Urol Clin North Am. 1997. 24:71–80.

184. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993. 6:428–442.

185. Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004. 53:Suppl 2. ii67–ii74.

186. Pietrow PK, Preminger GM. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Evaluation and medical management of urinary lithiasis. Campbell-Walsh Urology. 2007. 9th ed. Philadelphia: WB Saunders Elsevier.

187. Kim HW, Kim SH, Kim SW, Jung KI, Min KO, Cho SY. Effects of Subclinical Prostatitis on Benign Prostatic Hyperplasia. Korean J Urol. 2009. 50:154–158.

188. Schaeffer AJ, Anderson RU, Krieger JN. McConnell J, Abrams P, Denis L, Khoury S, Roehrborn C, editors. The assessment and management of male pelvic pain syndrome, including prostatitis. Male lower uninary tract dysfunction, evaluation and management; 6th international consultation on new developments in prostate cancer and prostate disease. 2006. Paris: Health Publications;341–385.

189. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection. 1991. 19:Suppl 3. S119–S125.

190. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999. 84:976–981.

191. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004. 172:S6–S11.

192. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999. 282:236–237.

193. Millán-Rodríguez F, Palou J, Bujons-Tur A, Musquera-Felip M, Sevilla-Cecilia C, Serrallach-Orejas M, Baez-Angles C, Villavicencio-Mavrich H. Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol. 2006. 24:45–50.

194. Ha US, Kim ME, Kim CS, Shim BS, Han CH, Lee SD, Cho YH. Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents. 2008. 31:Suppl 1. S96–S101.

195. Cho SY, Bae WJ, Cho YH, Lee SJ. Clinical characteristics and treatment results of acute bacterial prostatitis. Infect Chemother. 2009. 41:36–41.

196. Cho IR, Lee KC, Lee SE, Jeon JS, Park SS, Sung LH, Noh CH, Yang WJ, Choi YD, Hong SJ, Yang SC, Cho JS, Ahn HS, Kim SJ, Kim HS, Song KH, Seong DH, Suh JK, Lee KS, Song YS, Lee DH, Kim YS. Clinical outcome of acute bacterial prostatitis, a multicenter Study. Korean J Urol. 2005. 46:1034–1039.

197. Brook I. Urinary tract and genito-urinary suppurative infections due to anaerobic bacteria. Int J Urol. 2004. 11:133–141.

198. Naber KG. Management of bacterial prostatitis: what's new? BJU Int. 2008. 101:Suppl 3. 7–10.

199. Nickel JC, Moon T. Chronic bacterial prostatitis; An evolving clinical enigma. Urology. 2005. 66:2–8.

200. Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA, Wright PA, Wu SC, Zadeikis N, Kahn JB. Levofloxacin versus ciprofloxacin in the Treatment of Chronic Bacterial Prostatitis: A randomised double-blind multicenter study. Urology. 2003. 62:537–541.

201. Pewitt EB, Schaeffer AJ. Urinary tract infection in urology, including acute and chronic prostatitis. Infect Dis Clin North Am. 1997. 11:623–646.

202. Leigh DA. Prostatitis - an increasing clinical problem for diagnosis and management. J Antimicrob Chemother. 1993. 32:suppl A. 1–9.

203. Meares EM Jr. Acute and chronic prostatitis: diagnosis and treatment. Infect Dis Clin North Am. 1987. 1:855–873.

204. Ludwig M. Diagnosis and therapy of acute prostatitis, epididymitis and orchitis. Andrologia. 2008. 40:76–80.

205. Kravchick S, Cytron S, Agulansky L, Ben-Dor D. Acute prostatitis in middle-aged men: a prospective study. BJU Int. 2004. 93:93–96.

206. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968. 5:492–518.

207. Etienne M, Chavanet P, Sibert L, Michel F, Levesque H, Lorcerie B, Doucet J, Pfitzenmeyer P, Caron F. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis. 2008. 8:12.

208. Schaeffer AJ. Prostatitis: US perspective. Int J Antimicrob Agents. 1999. 11:205–211.

209. Meares EM Jr. Prostatic abscess. J Urol. 1986. 136:1281–1282.

210. Paulson DF, White RD. Trimethoprim-sulfamethoxazole and minocycline-hydrochloride in the treatment of culture-proved bacterial prostatitis. J Urol. 1978. 120:184–185.

211. Meares EM. Long-term therapy of chronic bacterial prostatitis with trimethoprim-sulfamethoxazole. Can Med Assoc J. 1975. 112:22–25.

212. McGuire EJ, Lytton B. Bacterial prostatitis: treatment with trimethoprim-sulfamethoxazole. Urology. 1976. 7:499–500.

213. Bjerklund Johansen TE, Gruneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, Palou Redorta J, van Cangh PJ. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. 1998. 34:457–466.

214. Wagenlehner FM, Naber KG. Prostatitis: the role of antibiotic treatment. World J Urol. 2003. 21:105–108.

215. Naber KG. Nickel JC, editor. Antibiotic treatment of chronic bacterial prostatitis. Textbook of Prostatitis. 1999. Oxford: Isis Medical Media;285–292.

216. Malinverni R, Glauser MP. Comparative studies of fluoroquinolones in the treatment of urinary tract infections. Rev Infect Dis. 1988. 10:Suppl 1. S153–S163.

217. Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis. 1989. 11:Suppl 5. S1321–S1337.

218. Naber KG, Busch W, Focht J. The German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prosatatitis: A prospective, non-comparative multicentre clinical trial with long-term follow-up. Int J Antimicrob Agents. 2000. 14:143–149.

219. Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA, Wright PA, Wu SC, Zadeikis N, Kahn JB. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology. 2003. 62:537–541.

220. Naber KG. European Lomefloxacin Prostatitis Study Group. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents. 2002. 20:18–27.

221. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, Barbone F, Selli C. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother. 2007. 19:304–308.

222. Bjerklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, Palou Redorta J, van Cangh PJ. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. 1998. 34:457–466.

223. Kurzer E, Kaplan S. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatits. Eur Urol. 2002. 42:163–166.

224. Oh CS, Cheon SH, Park RJ, Lee MS. The Efficacy of Oral Levofloxacin in the Treatment of Patient with Chronic Prostatitis. Infect Chemother. 2005. 37:99–103.

225. Park RJ, Chung JS, Kim SR, Lee SH. The Efficacy of Oral Ciprofloxacin in the Treatment of Patients with Chronic Prostatitis. J Korean Soc Chemother. 1999. 17:229–238.

226. Pust RA, Ackenheil-Koppe HR, Gilbert P, Weidner W. Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results. J Chemother. 1989. 1:4 Suppl. 869–871.

227. Weidner W, Schiefer HG, Dalhoff A. Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. Am J Med. 1987. 82:280–283.

228. Peppas T, Petrikkos G, Deliganni V, Zoumboulis P, Koulentianos E, Giamarellou H. Efficacy of long-term therapy with norfloxacin in chronic bacterial prostatitis. J Chemother. 1989. 1:4 Suppl. 867–868.

229. Pfau A. The treatment of chronic bacterial prostatitis. Infection. 1991. 19:Suppl 3. S160–S164.

230. Frazier HA, Spalding TH, Paulson DF. Total prostatoseminal vesiculectomy in the treatment of debilitating perineal pain. J Urol. 1992. 148:409–411.

231. Lee KC, Jung PB, Park HS, Whang JH, Lee JG. Transurethral needle ablation for chronic nonbacterial prostatitis. BJU Int. 2002. 89:226–229.

232. Skerk V, Schönwald S, Krhen I, Markovinović L, Barsić B, Mareković I, Roglić S, Zeljko Z, Vince A, Cajić V. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother. 2002. 14:384–389.

233. Skerk V, Schönwald S, Krhen I, Banaszak A, Begovac J, Strugar J, Strapac Z, Vrsalovic R, Vukovic J, Tomas M. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents. 2003. 21:457–462.

234. Skerk V, Krhen I, Lisić M, Begovac J, Roglić S, Skerk V, Sternak SL, Banaszak A, Strugar-Suica J, Vuković J. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents. 2004. 24:188–191.

TOOLS

Similar articles